Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$38.93 USD
-0.41 (-1.04%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.90 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.93 USD
-0.41 (-1.04%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.90 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Earnings Preview: Collegium Pharmaceutical (COLL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate
by Zacks Equity Research
Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.
Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?
Sage Therapeutics Soars: Stock Adds 7.1% in Session
by Zacks Equity Research
Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Valeant (VRX) in Focus: Stock Moves 11.7% Higher
by Zacks Equity Research
Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Top Ranked Momentum Stocks to Buy for November 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th:
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd:
Collegium (COLL) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Collegium Pharmaceutical (COLL) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
Top Ranked Momentum Stocks to Buy for November 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th:
Top Ranked Momentum Stocks to Buy for November 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 14th:
Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.
BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
by Zacks Equity Research
BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.
BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.